Everolimus-associated alveolar hemorrage relapse after drug discontinuation in a kidney transplant recipient

J Nephrol. 2022 May;35(4):1275-1278. doi: 10.1007/s40620-022-01298-w. Epub 2022 Mar 14.

Authors

Marco Busutti¹, Alessandra Cingolani², Filippo Natali³, Maria Mattiotti², Valeria Grandinetti², Olga Baraldi², Giorgia Comai², Piero Candoli³, Gaetano La Manna²

Affiliations

¹ Nephrology, Dialysis and Transplant Unit, IRCCS Policlinico Sant'Orsola, Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. marco.busutti@live.com.
² Nephrology, Dialysis and Transplant Unit, IRCCS Policlinico Sant'Orsola, Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
³ Interventional Pulmonology Unit, IRCCS Policlinico Sant'Orsola, Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

No abstract available

Keywords: Everolimus; Kidney; Lung; Toxicity; Transplant.

MeSH terms

Everolimus* / adverse effects
Graft Rejection / prevention & control
Humans
Immunosuppressive Agents / adverse effects
Kidney Transplantation* / adverse effects
Recurrence
Transplant Recipients

Substances

Immunosuppressive Agents
Everolimus